BioSpace News Archive

It’s been another strong week of biopharma companies making their debut on a stock exchange. Over the past 48 hours, three companies, Finch Therapeutics, Connect Biopharma and Gain Therapeutics, all made their debut on the Nasdaq.

A Phase III trial from Idera Pharmaceuticals did not reach the primary endpoint of ORR in patients with anti-PD-1 refractory advanced melanoma treated with a combination regimen comprising ipilimumab and the company’s investigational agent tilsotolimod.

A new nonhuman primate Alzheimer’s disease model developed by researchers from University of California, Davis and elsewhere could open the door to getting better therapies into human testing.

Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2020 and provided an update on clinical development programs with GEN-1

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines

Abattis Bioceuticals Corp. (“Abattis” or the “Company”) (OTC:ATTBF) is pleased to announce significant progress regarding its dealings with the British Columbia Securities Commission, the Class Action Lawsuit and its Operations

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will take place virtually from April 10-15 and May 17-21, 2021.

Leading cardiothoracic surgeon and researcher, Brendon Stiles, M.D., has been appointed chief of the division of thoracic surgery & surgical oncology in the department of cardiothoracic and vascular surgery at Montefiore Health System and Albert Einstein College of Medicine.

Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK program designed to develop and progress innovative oncology projects